View clinical trials related to Emergencies.
Filter by:To provide ruxolitinib through an expanded access program for the treatment of cytokine storm due to COVID-19 in the United States to patients who are eligible but not able to be hospitalized or who are hospitalized with a clinical diagnosis and/or positive test for SARD-CoV-2 infection.
This study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.